88 completed, 23 recruiting, 21 terminated, 20 active not recruiting. 126 Phase 2, 54 Phase 1, 19 Phase 3, 6 Not applicable, 5 Phase 4.
Follow Brentuximab Vedotin: new trials by email Literature Review of Brentuximab Vedotin trials Research Report on Brentuximab Vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2026-10-01 | 2026-08-20 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain Brentuximab Vedotin Plus CHP - CD30-Positive Peripheral T-Cell Lymphoma | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 100 | 2026-02-15 | 2026-06-03 | |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance Brentuximab Vedotin (Bv), Placebo - Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2025-11-01 | 2025-09-17 |
| Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) - Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Recruiting | New York Medical College | 20 | 2025-08-07 | 2026-05-20 |
| BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma Brentuximab Vedotin, Etoposide, Cyclophosphamide - Hodgkin Lymphoma, Advanced Hodgkin Lymphoma | Phase 2 | Recruiting | University of Miami | 48 | 2025-07-15 | 2025-11-03 |
| BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab - Hodgkin Lymphoma (Category) | Phase 4 | Not yet recruiting | Xiuhua Sun | 100 | 2024-12-31 | 2025-01-07 |
| Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide), Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide), Maintenance therapy-chidamide - CD30+ Peripheral T-cell Lymphoma | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 47 | 2024-11-01 | 2025-07-20 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 4 | Recruiting | Takeda | 124 | 2024-08-28 | 2026-02-23 |
| Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody. - Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | Phase 2 | Recruiting | Chinese PLA General Hospital | 100 | 2024-06-01 | 2026-01-02 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Open Label Extension Study of Brentuximab Vedotin in Early dcSSc Brentuximab vedotin - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 | 2024-02-14 | 2026-09-30 |
| CD30 Imaging in Diffuse Large B-cell Lymphoma Brentuximab vedotin - Diffuse Large B-cell-lymphoma | Phase 3 | Unknown | University Medical Center Groningen | 20 | 2024-01-01 | 2024-01-02 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2023-12-14 | 2026-10-06 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma Brentuximab vedotin, Pembrolizumab - T-Cell Lymphoma | Phase 2 | Recruiting | Yale University | 32 | 2023-07-10 | 2026-06-11 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-29 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
Showing 20 of 188. Sign in to see all of them.
Hodgkin Disease (80) · Lymphoma (35) · Lymphoma, Large-Cell, Anaplastic (26) · Hematologic Diseases (21) · Recurrence (19) · Lymphoma, Non-Hodgkin (17) · Lymphoma, T-Cell, Peripheral (14) · Lymphoma, T-Cell (13) · Lymphoma, T-Cell, Cutaneous (13) · Lymphoma, Large B-Cell, Diffuse (10) · Mycosis Fungoides (10) · Lymphatic Diseases (5) · Lymphoma, B-Cell (5) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (5) · Neoplasms (5)
Seagen Inc. (27) · National Cancer Institute (NCI) (13) · Takeda (11) · City of Hope Medical Center (9) · M.D. Anderson Cancer Center (8) · Fondazione Italiana Linfomi - ETS (5) · Massachusetts General Hospital (5) · Memorial Sloan Kettering Cancer Center (5) · Millennium Pharmaceuticals, Inc. (4) · The Lymphoma Academic Research Organisation (4) · University of Cologne (4) · Bristol-Myers Squibb (3) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (3) · New York Medical College (3) · Northwestern University (3)
United States (122) · France (24) · Italy (23) · Spain (22) · Canada (21) · United Kingdom (18) · Belgium (13) · Poland (13) · Germany (12) · Czechia (11) · Australia (9) · China (8) · Denmark (7) · Japan (7) · Netherlands (7)
Alex F Herrera (5) · Dana Kennedy, PharmD (3) · Peter Borchmann, Prof. (3) · Thomas Manley, MD (3) · Alex Herrera (2) · Alison Moskowitz, MD (2) · Lubomir Sokol, M.D., Ph.D. (2) · Mitchell Cairo, MD (2) · Naomi Hunder, MD (2) · Neil Josephson, MD (2)
PMID 40135712, PMID 37505794, PMID 22510871, PMID 32596842, PMID 17242396, PMID 24239220, PMID 24652992, PMID 25135998, PMID 28188133, PMID 28600132, PMID 28974506, PMID 33827139, PMID 34780623, PMID 37722357, PMID 39620432, PMID 12097283, PMID 1244564, PMID 18079362, PMID 19466965, PMID 19597183, PMID 19789316, PMID 21047225, PMID 21270441, PMID 21576639, PMID 22080439, PMID 22454421, PMID 22614995, PMID 22786877, PMID 22919026, PMID 23624209, PMID 23674495, PMID 23716537, PMID 23719719, PMID 23754575, PMID 23818604, PMID 24359243, PMID 24642247, PMID 25113753, PMID 25533035, PMID 25573987, PMID 25683846, PMID 25796459, PMID 26195720, PMID 26211987, PMID 26377597, PMID 26542718, PMID 26770954, PMID 26994848, PMID 27432875, PMID 27458003
P30CA033572 (4), U10CA180886 (4), 2014 (3), 2015 (3), 2023 (3), P30CA015083 (3), P30CA015704 (3), U10CA180820 (3), 2008 (2), 2016 (2), U10CA098543 (2), 2009 (1), 2017 (1), 2018 (1), 2019 (1)